HIV Prevention
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir
Gilead Sciences, lenacapavir, HIV prevention, PrEP, long-acting injectable, FDA approval, HIV sales, clinical trials, PURPOSE studies
ViiV Healthcare’s Multifaceted Approach to Combating HIV in Black Communities
ViiV Healthcare, HIV prevention, Black communities, Risk to Reasons, community grants, stigma reduction, education, access to care
Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude
HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers
HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare